Biogen’s latest evolution is more than just a nominal shift, according to its CEO, as the Big Biotech lops the Idec from its name and hopes to parlay its success in multiple sclerosis into some tough-to-treat diseases.

…read more

Source: Biogen’s future: Bigger bets on CNS, smaller name


0 No comments